We investigated the influence of 55 583 autophagy-related single-nucleotide polymorphisms (SNPs) on chronic lymphocytic leukemia (CLL) risk across 4 independent populations comprising 5472 CLL cases and 726 465 controls. We also examined their impact on overall survival (OS), time to first treatment (TTFT), autophagy flux, and immune responses. A meta-analysis of the 4 populations identified, to our knowledge, for the first time, significant associations between CDKN2A (rs3731204) and BCL2 (rs4940571, rs12457371, and rs1026825) SNPs and CLL risk, with CDKN2A showing the strongest association (P = 1.57 × 10−12). We also validated previously reported associations for FAS, BCL2, and BAK1 SNPs with CLL risk (P = 4.73 × 10−21 to 3.39 × 10−9). The CDKN2Ars3731204 and FASrs1926194 SNPs associated with increased CDKN2A and ACTA2 messenger RNA expression levels in the whole blood and/or lymphocytes (P = 5.1 × 10−7, P = 1.58 × 10−21, and P = 7.8 × 10−41), although no significant effect on autophagy flux was observed. However, associations were found between CDKN2A, BCL2, and FAS SNPs and various T-cell subsets, cytokine production, and circulating concentrations of interferon gamma, tumor necrosis factor–related apoptosis-inducing ligand, CD40, chemokine ligand 20, and interleukin-2 receptor subunit β proteins (P ≤ .005). No significant association was detected between autophagy variants and OS or TTFT, suggesting that these variants drive disease initiation rather than progression. In conclusion, this study identified 4 novel associations for CLL and provided insights into the biological pathways that influence CLL development.

Identification of 4 autophagy-related genetic variants as risk factors for chronic lymphocytic leukemia / Cabrera-Serrano, A.J., Sanchez-Maldonado, J.M., Rodriguez-Sevilla, J.J., Reyes-Zurita, F.J., Collado, R., Puiggros, A., Cornejo-Calvo, E., Garcia-Martin, P., Ter Horst, R., Benavente, Y., Jerez, A., Landi, S., Espinet, B., Maffei, R., Lopez-Nevot, M.A., Ramos-Campoy, S., Gonzalez-Olmedo, C., Chen-Liang, T.-H., Moreno, V., Jannus, F., et al.. - In: BLOOD ADVANCES. - ISSN 2473-9529. - 9:23(2025), pp. 6076-6089. [10.1182/bloodadvances.2025017345]

Identification of 4 autophagy-related genetic variants as risk factors for chronic lymphocytic leukemia

Maffei R.;Luppi M.;Marasca R.;
2025

Abstract

We investigated the influence of 55 583 autophagy-related single-nucleotide polymorphisms (SNPs) on chronic lymphocytic leukemia (CLL) risk across 4 independent populations comprising 5472 CLL cases and 726 465 controls. We also examined their impact on overall survival (OS), time to first treatment (TTFT), autophagy flux, and immune responses. A meta-analysis of the 4 populations identified, to our knowledge, for the first time, significant associations between CDKN2A (rs3731204) and BCL2 (rs4940571, rs12457371, and rs1026825) SNPs and CLL risk, with CDKN2A showing the strongest association (P = 1.57 × 10−12). We also validated previously reported associations for FAS, BCL2, and BAK1 SNPs with CLL risk (P = 4.73 × 10−21 to 3.39 × 10−9). The CDKN2Ars3731204 and FASrs1926194 SNPs associated with increased CDKN2A and ACTA2 messenger RNA expression levels in the whole blood and/or lymphocytes (P = 5.1 × 10−7, P = 1.58 × 10−21, and P = 7.8 × 10−41), although no significant effect on autophagy flux was observed. However, associations were found between CDKN2A, BCL2, and FAS SNPs and various T-cell subsets, cytokine production, and circulating concentrations of interferon gamma, tumor necrosis factor–related apoptosis-inducing ligand, CD40, chemokine ligand 20, and interleukin-2 receptor subunit β proteins (P ≤ .005). No significant association was detected between autophagy variants and OS or TTFT, suggesting that these variants drive disease initiation rather than progression. In conclusion, this study identified 4 novel associations for CLL and provided insights into the biological pathways that influence CLL development.
2025
9
23
6076
6089
Identification of 4 autophagy-related genetic variants as risk factors for chronic lymphocytic leukemia / Cabrera-Serrano, A.J., Sanchez-Maldonado, J.M., Rodriguez-Sevilla, J.J., Reyes-Zurita, F.J., Collado, R., Puiggros, A., Cornejo-Calvo, E., Garcia-Martin, P., Ter Horst, R., Benavente, Y., Jerez, A., Landi, S., Espinet, B., Maffei, R., Lopez-Nevot, M.A., Ramos-Campoy, S., Gonzalez-Olmedo, C., Chen-Liang, T.-H., Moreno, V., Jannus, F., et al.. - In: BLOOD ADVANCES. - ISSN 2473-9529. - 9:23(2025), pp. 6076-6089. [10.1182/bloodadvances.2025017345]
Cabrera-Serrano, A. J.; Sanchez-Maldonado, J. M.; Rodriguez-Sevilla, J. J.; Reyes-Zurita, F. J.; Collado, R.; Puiggros, A.; Cornejo-Calvo, E.; Garcia-...espandi
File in questo prodotto:
File Dimensione Formato  
blooda_adv-2025-017345-main.pdf

Open access

Tipologia: VOR - Versione pubblicata dall'editore
Licenza: [IR] creative-commons
Dimensione 670.73 kB
Formato Adobe PDF
670.73 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1404816
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact